NUMD (Nu-Med Plus) FCF Yield %: -4.25 (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Nu-Med Plus FCF Yield %?

Nu-Med Plus NUMD FCF Yield % is -4.25 as of Jul. 22, 2026. The stock has 1 warning sign investors should review. Among 853 Medical Devices & Instruments companies, Nu-Med Plus ranks worse than 63.19% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Nu-Med Plus's Trailing 12-Month Free Cash Flow is $-0.05 Mil, and Market Cap is $1.27 Mil. Therefore, Nu-Med Plus's FCF Yield % for today is -4.25%.

The historical rank and industry rank for Nu-Med Plus's FCF Yield % or its related term are showing as below:

NUMD' s FCF Yield % Range Over the Past 10 Years
Min: -4.25   Med: 0   Max: 0
Current: -4.25


NUMD's FCF Yield % is ranked worse than
63.19% of 853 companies
in the Medical Devices & Instruments industry
Industry Median: -0.42 vs NUMD: -4.25

Nu-Med Plus's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.


Nu-Med Plus FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Nu-Med Plus FCF Yield % Related Terms


Nu-Med Plus FCF Yield % Historical Data

* Premium members only.

The historical data trend for Nu-Med Plus's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nu-Med Plus FCF Yield % Chart

Nu-Med Plus Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.45 -2.83 -1.95 -0.31 -3.32

Nu-Med Plus Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.20 -1.69 -9.70 -2.61

NUMD vs SSKN, ODYY, NUWE: FCF Yield % Comparison

For the Medical Devices subindustry, Nu-Med Plus's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nu-Med Plus FCF Yield % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nu-Med Plus's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Nu-Med Plus's FCF Yield % falls into.



Nu-Med Plus FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Nu-Med Plus's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-0.048 / 1.44370944
=-3.32%

Nu-Med Plus's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-0.006 * 4 / 0.919028
=-2.61%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -4.25 mean?
Nu-Med Plus (NUMD) has a FCF Yield % of -4.25 as of Jul. 22, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Nu-Med Plus and its competitors. According to the industry distribution chart, Nu-Med Plus ranks #539 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 63.2%.
Is Nu-Med Plus' FCF Yield % too high?
Nu-Med Plus' current FCF Yield % is -4.25. Based on the distribution chart, Nu-Med Plus ranks #539 out of 853 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does Nu-Med Plus' FCF Yield % compare to SSKN and ODYY?
According to the Medical Devices & Instruments industry distribution chart, Nu-Med Plus ranks #539 out of 853 companies for FCF Yield %. This places Nu-Med Plus in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Nu-Med Plus and its competitors. Nu-Med Plus's current FCF Yield % is -4.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nu-Med Plus stock overvalued right now?
Nu-Med Plus (NUMD) has a current FCF Yield % of -4.25. The current FCF Yield % is -4.25. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Nu-Med Plus (NUMD), the current FCF Yield % is -4.25 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nu-Med Plus Business Description

Address 640 Belle Terre Road, Building 2 E Port, Jefferson, NY, USA, 11777
Nu-Med Plus Inc is a medical device company engaged in the design, innovation, development, enhancement, and commercialization of beginning, early, and selective later-stage quality medical devices. It focuses on the formulation of Nitric Oxide powder, which is a desktop generator device which delivers inhaled Nitric Oxide to replace expensive pressurized canisters and a mobile rechargeable device to deliver inhaled Nitric Oxide gas to offer solutions to hospitals, health systems, and the medical community throughout the world. It is currently working to locate a merger partner that will be able to fund the final development of these products.